Big takeaways from #ELCC2025 are shaking up lung cancer surgery. In the latest STS Best of Lung Cancer Science podcast, Dr. Erin Gillaspie sits down with Dr. Paula Uglade about restaging, resectability, AI in care, and the de-escalation debate. Tune in: https://ow.ly/TSqo50XWrwn
#CTsurgery

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in <em>EGFR</em>-Mutated Non–Small Cell Lung Cancer The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed…

At #ELCC2025, final survival results from the phase III MARIPOSA trial showed that patients with EGFR-mutated non–small cell lung cancer lived significantly longer when treated with amivantamab-vmjw plus lazertinib compared to osimertinib. #lungcancer
ascopost.com/issues/may-1...

Our Investigator Initiated Trial, POTENT, presented at #ELCC2025 by Dr Anna Minchom combines tepotinib + pembrolizumab to tackle immune resistance in NSCLC.
Promising early results prelude to expanding treatment options & improving outcomes for NSCLC patients.

#LungCancer #DDUIIT

Evolving approaches for mediastinal nodal involvement in NSCLC - VJOncology Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, comments on the evolving field of mediastinal nodal involvement in...

🎥Dr Paul van Schil discusses mediastinal nodal involvement in #lungcancer at #ELCC2025.

🫁 Restaging may help guide treatment, but more research is needed to define best practices:

Learn more here➡️https://buff.ly/Tc6G7QO⬅️

@myESMO #LungCancer #LCSM

Optimizing immunosuppressive strategies for managing immune-related adverse events in lung cancer - VJOncology Umair Mahmood, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares insights on optimizing immunosuppressive strategies to manage immune-related adverse...

🎥Dr Umair Mahmood shares strategies to manage irAEs in lung cancer. Lower-dose steroids (≤60mg prednisolone) may improve outcomes; infliximab’s role also under review:

➡️https://buff.ly/QxG68iI⬅️

#ELCC2025 #LungCancer #LCSM #ImmunoOnc

Treating patients with NSCLC who progress on ROS1 inhibitors - VJOncology Misako Nagasaka, MD, UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, gives an overview of treatment options for patients...

🎥Dr Misako Nagasaka discusses next steps for patients with #NSCLC progressing on ROS1 inhibitors, highlighting emerging drugs like repotrectinib & NVL-520:

Learn more here➡️https://buff.ly/Z7qsKqI⬅️

#ELCC2025 #LungCancer #LCSM

Deciding the best treatment strategy for borderline resectable NSCLC - VJOncology Isabelle Schmitt-Opitz, MD, University Hospital Zurich, Zurich, Switzerland, comments on the challenges of managing borderline resectable non-small cell lung cancer...

🎥 Prof. Isabelle Schmitt-Opitz discusses the challenges of managing borderline resectable #NSCLC & N2 disease, highlighting the need for case-by-case decisions & the role of induction immunochemotherapy plus surgery:

Learn more here ➡️ buff.ly/uNXkmfV ➡️

#ELCC2025 #LungCancer

Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC
#ELCC2025 #LCSM
www.onclive.com/view/subcuta...

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC @myesmo.bsky.social #ELCC2025 #lcsm #oncology
www.onclive.com/view/savolit...

Sie brauchen noch eine kleine Lektüre vor dem Wochenende? 📚 @hochmairmaximilian.bsky.social stellte 2 Poster auf dem #ELCC2025 vor: Link im Kommentar #NSCLC #ELCC2025

Cancer du poumon métastatique non à petites cellules : des progrès notables dans la prise en charge Duo de thérapies ciblées plus efficaces, stratégies de réduction des effets secondaires, immunothérapies en sous-cutané, algorithmes prédictifs de la réponse à l’immunothérapie, des avancées importantes ont été présentées dans le CBNPC lors du congrès européen sur le cancer du poumon.

Cancer du poumon métastatique non à petites cellules : des progrès notables dans la prise en charge #ELCC2025
http://ms.spr.ly/63325qqutc

Highlights from ELCC Day 3 - OncoDaily Highlights from ELCC Day 3 / Alessandra Dodi, Alfredo Addeo, Amol Akhade, Antonio Calles, cancer, ELCC, ELCC 2025, ELCC25, Eric Halioua, ESMO, Giannis

Highlights from ELCC Day 3

@suyogcancer.bsky.social
@drgreeklungcancer.bsky.social
@drjnaidoo.bsky.social

oncodaily.com/societies/26...

#Cancer #ELCC #ELCC2025 #ELCC25 #ESMO #LungCancer #NSCLC #OncoDaily #Oncology #ThoracicOncology #Medicine #Health

Osimertinib after definitive chemoradiotherapy is a "new standard of care" in unresectable, stage III, EGFR-mutant NSCLC, reported @ramalingammd.bsky.social of @winshipatemory.bsky.social in an updated analysis of the LAURA study presented at #ELCC25. #ELCC2025 #lcsm

#BiotechHangout: Chris Garabedian, Tim Opler, Bruce Booth & Sam Fazeli on investor mood, PIPEs, startup contraction, policy updates: (FDA, NIH, CDC, HHS) data: ($CGON, $SLNO), #ELCC2025: ($JNJ, $AZN, $BNTX), $NVO’s obesity deals, aging report, $LYRA wind-down & more: twitter.com/i/spaces/1MY...

Taletrectinib improves outcomes compared to crizotinib in TKI-naive patients with ROS1-positive NSCLC, according to research presented at #ELCC25 by Dr. Misako Nagasaka of the University of California Irvine School of Medicine. #ELCC2025 #lcsm

Subcutaneous pembrolizumab is noninferior to intravenous pembro in treatment-naive metastatic NSCLC, according to results presented at #ELCC25 by Dr. Enriqueta Felip of @vallhebroncampus.bsky.social. #ELCC2025 #lcsm

First-line fulzerasib + cetuximab leads to "deep and durable efficacy" in NSCLC, according to results presented at #ELCC25 by Dr Margarita Majem of Hospital de la Santa Creu i Sant Pau in Barcelona. #ELCC2025 #lcsm

A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.

#ELCC2025

Osimertinib + Dato-DXd "demonstrated promising efficacy" in patients with EGFR-mutant, advanced NSCLC whose disease progressed after 1st-line osimertinib, said Dr Xiuning Le of @mdanderson.bsky.social. She presented these results, from the phase 2 ORCHARD trial, at #ELCC25. #ELCC2025 #lcsm

Congratulations to Keith Kerr, a long-time IASLC member, for receiving the 2025 Heine H Hansen Award at #ELCC2025 👏🏽👏🏽

ONE week left to submit your work for ELCC 2025 - ESMO - OncoDaily ONE week left to submit your work for ELCC 2025 - ESMO / cancer, ELCC 2025, ESMO, OncoDaily, Oncology

ONE week left to submit your work for ELCC 2025 – ESMO

oncodaily.com/blog/elcc202...

#Cancer #ELCC2025 #ESMO #OncoDaily #Oncology #Medicine #Health